Dermatologic https://www.bioworld.com/rss en-us Chiesi snags on-demand HAE drug in $1.9B Kalvista buy http://www.bioworld.com/articles/730681 Wed, 29 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730681-chiesi-snags-on-demand-hae-drug-in-19b-kalvista-buy Ekterly pill and packaging Credit: Kalvista Pharmaceuticals Inc. Sun Pharma to acquire Merck spinoff Organon for $11.75B http://www.bioworld.com/articles/730787 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Sun Pharma to acquire Merck spinoff Organon for $11.75B http://www.bioworld.com/articles/730643 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target MANE event: Veradermics beats expectations in pattern hair loss trial http://www.bioworld.com/articles/730639 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730639-mane-event-veradermics-beats-expectations-in-pattern-hair-loss-trial Male hair loss Dupi whoopie: Sanofi/Regeneron cheered for sales, new approval http://www.bioworld.com/articles/730601 Thu, 23 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730601-dupi-whoopie-sanofi-regeneron-cheered-for-sales-new-approval Dupixent Daiichi to divest consumer health unit to Suntory for $1.5B http://www.bioworld.com/articles/730574 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions Nektar’s rezpeg more than worth its SALT in alopecia phase IIb http://www.bioworld.com/articles/730481 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730481-nektars-rezpeg-more-than-worth-its-salt-in-alopecia-phase-iib Hand showing bald patch of scalp Daiichi to divest consumer health unit to Suntory for $1.5B http://www.bioworld.com/articles/730407 Fri, 17 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b Two arrows in opposite directions US FDA cites first dispenser for violating Rx supply chain act http://www.bioworld.com/articles/730300 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730300-us-fda-cites-first-dispenser-for-violating-rx-supply-chain-act FDA sign Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal http://www.bioworld.com/articles/730297 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal Open capsule delivering pain relief to body Biohaven’s BHV-1450 shows promise for pemphigus vulgaris http://www.bioworld.com/articles/730331 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730331-biohavens-bhv-1450-shows-promise-for-pemphigus-vulgaris Lab glassware and antibodies art concept DXP-006 reduces disease severity in psoriasis models http://www.bioworld.com/articles/730258 Fri, 10 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730258-dxp-006-reduces-disease-severity-in-psoriasis-models Doctor holding illustration of cross section of skin Topical ASO restores WRN function for chronic skin ulcers in Werner syndrome C mutation.]]> http://www.bioworld.com/articles/730187 Wed, 08 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730187-topical-aso-restores-wrn-function-for-chronic-skin-ulcers-in-werner-syndrome Missing puzzle piece and broken DNA chain Nrf2 activator counteracts atopic dermatitis pathology http://www.bioworld.com/articles/730168 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730168-nrf2-activator-counteracts-atopic-dermatitis-pathology Simcere’s rademikibart meets phase III endpoints in atopic dermatitis http://www.bioworld.com/articles/729969 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis Monoclonal antibody illustration Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis http://www.bioworld.com/articles/730042 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730042-infinimmune-presents-preclinical-data-on-anti-il-22-antibody-for-atopic-dermatitis 3D illustration of antibodies HXN-1023 drives robust anti-inflammatory responses in atopic dermatitis models http://www.bioworld.com/articles/730040 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730040-hxn-1023-drives-robust-anti-inflammatory-responses-in-atopic-dermatitis-models Skin, tissue layer illustration NAV-242 bispecific antibody supports quarterly dosing in HS http://www.bioworld.com/articles/730036 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730036-nav-242-bispecific-antibody-supports-quarterly-dosing-in-hs AAD 2026: Targeted oral therapies challenge injected biologics http://www.bioworld.com/articles/729951 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729951-aad-2026-targeted-oral-therapies-challenge-injected-biologics Oral medication Multibody TEV‘325 achieves preclinical milestone http://www.bioworld.com/articles/729930 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone Illustration of a road with three destination markers Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729893 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss Market roomy, phase II zumi to reach dosing upside Apogee in AD? http://www.bioworld.com/articles/729808 Mon, 23 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729808-market-roomy-phase-ii-zumi-to-reach-dosing-upside-apogee-in-ad Skin irritation Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729749 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729749-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss Aqilion advances AQ-128 for psoriasis http://www.bioworld.com/articles/729721 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729721-aqilion-advances-aq-128-for-psoriasis Close up of hand scratching arm with psoriasis patches Icotyde’s in; wave of switchers to oral psoriasis Protagonist? http://www.bioworld.com/articles/729558 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729558-icotydes-in-wave-of-switchers-to-oral-psoriasis-protagonist Icotyde Credit: Johnson & Johnson Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729714 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729495 Fri, 13 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978 http://www.bioworld.com/articles/729627 Fri, 13 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729627-enanta-pharmaceuticals-presents-data-for-kit-inhibitor-edp-978 Illustration of a mast cell releasing histamines HX-16108 holds promise for treating inflammatory skin diseases http://www.bioworld.com/articles/729592 Wed, 11 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases Skin irritation on hands Kyowa Kirin discontinues rocatinlimab trials due to safety issues http://www.bioworld.com/articles/729583 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729583-kyowa-kirin-discontinues-rocatinlimab-trials-due-to-safety-issues Lab vials and dropper